Advanced search
Add to list

Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT)

(2019) HAEMATOLOGICA. 104(suppl. 2). p.7-8
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Pinto, A., et al. “Lenalidomide/Rituximab (R2) versus Rituximab/Placebo Efficacy by POD24 Status and Time to next Treatment in Patients with Relapsed/Refractory Indolent NHL (AUGMENT).” HAEMATOLOGICA, vol. 104, no. suppl. 2, 2019, pp. 7–8.
APA
Pinto, A., Gribben, J., Trneny, M., Izutsu, K., Fowler, N., Hong, X., … Leonard, J. (2019). Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT). HAEMATOLOGICA, 104(suppl. 2), 7–8.
Chicago author-date
Pinto, A, J Gribben, M Trneny, K Izutsu, NH Fowler, X Hong, H Zhang, et al. 2019. “Lenalidomide/Rituximab (R2) versus Rituximab/Placebo Efficacy by POD24 Status and Time to next Treatment in Patients with Relapsed/Refractory Indolent NHL (AUGMENT).” In HAEMATOLOGICA, 104:7–8.
Chicago author-date (all authors)
Pinto, A, J Gribben, M Trneny, K Izutsu, NH Fowler, X Hong, H Zhang, Fritz Offner, A Scheliga, G Nowakowski, F Re, LM Fogliatto, P Scheinberg, I Flinn, C Moreira, M Czuczman, S Kalambakas, P Fustier, C Wu, and JP Leonard. 2019. “Lenalidomide/Rituximab (R2) versus Rituximab/Placebo Efficacy by POD24 Status and Time to next Treatment in Patients with Relapsed/Refractory Indolent NHL (AUGMENT).” In HAEMATOLOGICA, 104:7–8.
Vancouver
1.
Pinto A, Gribben J, Trneny M, Izutsu K, Fowler N, Hong X, et al. Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT). In: HAEMATOLOGICA. 2019. p. 7–8.
IEEE
[1]
A. Pinto et al., “Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT),” in HAEMATOLOGICA, Rome, Italy, 2019, vol. 104, no. suppl. 2, pp. 7–8.
@inproceedings{8647130,
  articleno    = {{abstract C003}},
  author       = {{Pinto, A and Gribben, J and Trneny, M and Izutsu, K and Fowler, NH and Hong, X and Zhang, H and Offner, Fritz and Scheliga, A and Nowakowski, G and Re, F and Fogliatto, LM and Scheinberg, P and Flinn, I and Moreira, C and Czuczman, M and Kalambakas, S and Fustier, P and Wu, C and Leonard, JP}},
  booktitle    = {{HAEMATOLOGICA}},
  issn         = {{0390-6078}},
  language     = {{eng}},
  location     = {{Rome, Italy}},
  number       = {{suppl. 2}},
  pages        = {{abstract C003:7--abstract C003:8}},
  title        = {{Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT)}},
  volume       = {{104}},
  year         = {{2019}},
}

Web of Science
Times cited: